Zegerid OTC arrives in April
This article was originally published in The Tan Sheet
Executive Summary
Zegerid OTC is slated to ship in late March and reach retail by April, says Santarus, the originator of the switched proton pump inhibitor. The firm reported March 3 its fourth-quarter earnings climbed 66.3 percent to $62.4 million - driven mainly by a $20 million regulatory approval milestone payment from Merck, which will market Zegerid OTC (omeprazole/sodium bicarbonate). Santarus said it expects to know by June whether FDA will allow an already-approved dual-buffer PPI to be marketed under the Zegerid brand